PMC:7534795 / 47173-47452 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T351","span":{"begin":40,"end":48},"obj":"Disease"},{"id":"T352","span":{"begin":261,"end":269},"obj":"Disease"}],"attributes":[{"id":"A351","pred":"mondo_id","subj":"T351","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A352","pred":"mondo_id","subj":"T352","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"For example, treatment of patients with COVID-19 with non-steroidal anti-inflammatory drugs, glucocorticoids and anti-viral agents, such as ribavirin, lopinavir/ritonavir, INF-α and the antibiotic azithromycin, could further increase the cardiovascular risk of COVID-19 patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T373","span":{"begin":54,"end":91},"obj":"Chemical"},{"id":"T374","span":{"begin":68,"end":91},"obj":"Chemical"},{"id":"T375","span":{"begin":86,"end":91},"obj":"Chemical"},{"id":"T376","span":{"begin":93,"end":108},"obj":"Chemical"},{"id":"T377","span":{"begin":113,"end":130},"obj":"Chemical"},{"id":"T378","span":{"begin":140,"end":149},"obj":"Chemical"},{"id":"T379","span":{"begin":151,"end":170},"obj":"Chemical"},{"id":"T380","span":{"begin":151,"end":160},"obj":"Chemical"},{"id":"T381","span":{"begin":161,"end":170},"obj":"Chemical"},{"id":"T382","span":{"begin":186,"end":196},"obj":"Chemical"},{"id":"T383","span":{"begin":197,"end":209},"obj":"Chemical"}],"attributes":[{"id":"A373","pred":"chebi_id","subj":"T373","obj":"http://purl.obolibrary.org/obo/CHEBI_35475"},{"id":"A374","pred":"chebi_id","subj":"T374","obj":"http://purl.obolibrary.org/obo/CHEBI_35472"},{"id":"A375","pred":"chebi_id","subj":"T375","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A376","pred":"chebi_id","subj":"T376","obj":"http://purl.obolibrary.org/obo/CHEBI_24261"},{"id":"A377","pred":"chebi_id","subj":"T377","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A378","pred":"chebi_id","subj":"T378","obj":"http://purl.obolibrary.org/obo/CHEBI_63580"},{"id":"A379","pred":"chebi_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A380","pred":"chebi_id","subj":"T380","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A381","pred":"chebi_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A382","pred":"chebi_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A383","pred":"chebi_id","subj":"T383","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"}],"text":"For example, treatment of patients with COVID-19 with non-steroidal anti-inflammatory drugs, glucocorticoids and anti-viral agents, such as ribavirin, lopinavir/ritonavir, INF-α and the antibiotic azithromycin, could further increase the cardiovascular risk of COVID-19 patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T405","span":{"begin":0,"end":279},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"For example, treatment of patients with COVID-19 with non-steroidal anti-inflammatory drugs, glucocorticoids and anti-viral agents, such as ribavirin, lopinavir/ritonavir, INF-α and the antibiotic azithromycin, could further increase the cardiovascular risk of COVID-19 patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1396","span":{"begin":172,"end":177},"obj":"Gene"},{"id":"1401","span":{"begin":26,"end":34},"obj":"Species"},{"id":"1402","span":{"begin":270,"end":278},"obj":"Species"},{"id":"1403","span":{"begin":140,"end":149},"obj":"Chemical"},{"id":"1404","span":{"begin":151,"end":170},"obj":"Chemical"},{"id":"1405","span":{"begin":197,"end":209},"obj":"Chemical"},{"id":"1414","span":{"begin":40,"end":48},"obj":"Disease"},{"id":"1415","span":{"begin":261,"end":269},"obj":"Disease"}],"attributes":[{"id":"A1396","pred":"tao:has_database_id","subj":"1396","obj":"Gene:3451"},{"id":"A1401","pred":"tao:has_database_id","subj":"1401","obj":"Tax:9606"},{"id":"A1402","pred":"tao:has_database_id","subj":"1402","obj":"Tax:9606"},{"id":"A1403","pred":"tao:has_database_id","subj":"1403","obj":"MESH:D012254"},{"id":"A1404","pred":"tao:has_database_id","subj":"1404","obj":"MESH:C558899"},{"id":"A1405","pred":"tao:has_database_id","subj":"1405","obj":"MESH:D017963"},{"id":"A1414","pred":"tao:has_database_id","subj":"1414","obj":"MESH:C000657245"},{"id":"A1415","pred":"tao:has_database_id","subj":"1415","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"For example, treatment of patients with COVID-19 with non-steroidal anti-inflammatory drugs, glucocorticoids and anti-viral agents, such as ribavirin, lopinavir/ritonavir, INF-α and the antibiotic azithromycin, could further increase the cardiovascular risk of COVID-19 patients."}